Anixa Biosciences Inc 2026年季度报告

FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2026 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number 001-37492 ANIXA BIOSCIENCES, INC. Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beensubject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Accelerated filer☐Non-accelerated filer☒Smaller reporting company☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. On June 10, 2026, the registrant had outstanding 34,023,063 shares of Common Stock, par value $.01 per share, which is the registrant’s onlyclass of common stock. TABLE OF CONTENTS PART I. FINANCIAL INFORMATIONItem 1. Financial Statements.1Condensed Consolidated Balance Sheets (Unaudited) as of April 30, 2026 and October 31, 20251Condensed Consolidated Statements of Operations (Unaudited) for the three and six months ended April 30, 2026 and 20252Condensed Consolidated Statements of Equity (Unaudited) for the three months ended April 30, 2026 and 20253Condensed Consolidated Statements of Equity (Unaudited) for the six months ended April 30, 2026 and 20254Condensed Consolidated Statements of Cash Flows (Unaudited) for the six months ended April 30, 2026 and 20255Notes to Condensed Consolidated Financial Statements (Unaudited)6Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.18Item 3. Quantitative and Qualitative Disclosures About Market Risk.22Item 4. Controls and Procedures.22PART II. OTHER INFORMATION23Item 1. Legal Proceedings.23Item 1A. Risk Factors.23Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.23Item 3. Defaults Upon Senior Securities.23Item 4. Mine Safety Disclosures.23Item 5. Other Information.23Item 6. Exhibits.23SIGNATURES24i PART I. FINANCIAL INFORMATION ANIXA BIOSCIENCES, INC. AND SUBSIDIARIESNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(UNAUDITED) 1. BUSINESS AND FUNDING Description of Business As used herein, “we,” “us,” “our,” the “Company” or “Anixa” means Anixa Biosciences, Inc. and its consolidated subsidiaries. Anixa Biosciences, Inc. is a biotechnology company developing therapies and vaccines that are focused on critical unmet needs inoncology. Our therapeutics program consists of the development of liraltagene autoleucel (“lira-cel”), a chimeric endocrine receptor-T celltherapy, which is a novel form of chimeric antigen receptor-T cell (“CAR-T”) technology, initially focused on treating ovarian cancer, that isbeing developed at our subsidiary, Certainty Therapeutics, Inc. (“Certainty”). Our vaccine programs include (i) the development of a vaccineagainst breast cancer, (ii) the development of a vaccine against ovarian cancer, and (iii) a vaccine discovery program utilizing the samemechanism as our breast and ovarian cancer vaccines to develop additional cancer vaccines to address many intractable cancers, including highincidence malignancies in lung, colon and prostate. Our subsidiary, Certainty, is developing immuno-therapy drugs against cancer. Certainty holds an exclusive worldwide, royalty-bearing license to use certain intellectual property owned or controlled by The Wistar Institute (“Wistar”), the nation’s first independentbiomedical research institute and a leading National Cancer Institute (“NCI”) designated cancer research center, relating to Wistar’s chimericendocrine receptor targeted t